abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Cardiovascular risk in Psoriatic Arthritis, a narrative review


Verhoeven F1, Prati C2, Demougeot C3, Wendling D4. Joint Bone Spine. 2020 Jan 17. pii: S1297-319X(20)30004-X. doi: 10.1016/j.jbspin.2019.12.004. [Epub ahead of print]

Author Information

1 Service de Rhumatologie, CHRU de Besançon, France; EA 4267 « PEPITE », Université de Bourgogne Franche Comté, France. Electronic address: fverhoeven@chu-besancon.fr.

2 Service de Rhumatologie, CHRU de Besançon, France; EA 4267 « PEPITE », Université de Bourgogne Franche Comté, France.

3 EA 4267 « PEPITE », Université de Bourgogne Franche Comté, France.

4 Service de Rhumatologie, CHRU de Besançon, France; EA 4266 «EPILAB », Université de Bourgogne Franche-Comté, France.



Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism characterized for a long time by a high degree of cardiovascular risk. Chronic inflammation is one of the mechanisms that explain this cardiovascular excess of risk through direct and indirect pathways. In recent years, epidemiological data have changed somewhat since the increasing use of bio-drugs that are effective in reducing this inflammation. The purpose of this review is to assess the current state of cardiovascular morbidity and mortality in PsA and thus to assess the cardiovascular risk in case of PsA.


We conducted a literature review using Pubmed and Medline databases with the following keywords "Psoriatic Arthritis "AND "cardiovascular" including articles from the last three years.


It appears that in case of PsA, there is an increased prevalence of high blood pressure, diabetes, obesity and dyslipidemia, and therefore of metabolic syndrome. Insulin resistance is closely linked to PsA. On the other hand, the data are more contrasted for active smoking. There is also arterial inflammation specific to PsA. Finally, at the therapeutic level, the impact of NSAIDs remains controversial, while methotrexate and bio-drugs are beneficial at the cardiovascular level.


PsA is characterized by an increase in cardiovascular morbidity in relation with insulin resistance. Current treatments seem to improve this risk with a decrease in cardiovascular mortality in comparison with patients with plaque psoriasis but this requires confirmation in larger prospective studies.